The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
14-Jan-15
$309 million
Target:
Chandler Macleod Group Limited
Acquiror:
Recruit Holdings Co.,Ltd
Advised Recruit Holdings Co.,Ltd, the leading global staffing services company in Japan, on the acquisition of Chandler Macleod Group Limited, a major general recruitment company
11-Aug-14
$NA
Target:
MannKind Corporation
Acquiror:
Sanofi
Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits.
05-Aug-14
$1.3 billion
Target:
Siemens Health Services
Acquiror:
Cerner Corporation
Advised Cerner Corporation, a leader in healthcare information services, on the acquisition of the assets of Siemens Aktiengesellschaft’s healthcare information technology business unit, Siemens Health Services, for $1.3 billion in cash.
28-Jul-14
$90 million
Target:
Clinuvel Pharmaceuticals Limited
Acquiror:
Retrophin, Inc.
Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases
08-Apr-14
$NA
Target:
ARTnews
Acquiror:
Skate Capital Corp.
Advised ARTnews, the world's oldest and most widely circulated art magazine, on its sale to Skate Capital Corp., a private art and media industry investment vehicle
18-Feb-14
$25.1 billion
Target:
Forest Laboratories Inc.
Acquiror:
Actavis plc
Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.
18-Dec-13
$NA
Target:
Global Television
Acquiror:
NEP Group Inc.
Advised Catalyst Investment Managers on the sale of its portfolio company Global Television, Australia’s largest provider of outsourced broadcasting and video production services, to NEP Inc., a leading provider of total broadcast solutions in the US, UK and Brazil. NEP is majority-owned by private funds managed by Crestview Partners
18-Dec-13
$141 million
Target:
Open Colleges Australia Pty Ltd
Acquiror:
Apollo Education Group, Inc.
Advised Open Colleges, Australia’s leading privately owned online provider in the high-growth vocational education and training sector, on the sale of a 70% stake (plus exit arrangements for the balance) to Apollo Education Group, Inc., one of North America’s largest private education providers
31-May-13
$500 million
Target:
iSelect (30% shareholding)
Acquiror:
Ninemsn (T/A Mi9)
Advised Mi9, a joint venture between Microsoft and Nine Entertainment Co, and one of Australia’s leading digital media companies, on the sale of its 30% holding in iSelect, a leading Australian online-driven comparison service, as part of the Initial Public Offering of iSelect
20-May-13
$8.5 billion
Target:
Warner Chilcott, plc
Acquiror:
Actavis, Inc.
Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc
15-Jan-13
$NA
Target:
Broadcast Rights for V8 Supercars
Acquiror:
Seven Network
Advised Archer Capital, a leading Australian private equity firm, and its portfolio company V8 Supercars Australia, on the sale of the Australian FTA television broadcasting rights for V8 Supercars to Seven, a leading Free to Air broadcaster in Australia
01-Nov-12
$180 million
Target:
SKY Network Television Limited
Advised Todd Corporation, a major New Zealand family office, on the divestment of its 11.1% holding in SKY Network Television Limited, New Zealand’s leading provider of pay television services
02-Sep-12
$285 million
Target:
DMG Radio Australia, a subsidiary of Daily Mail and Guardian Trust Plc
Acquiror:
Illyria Pty
Advised Daily Mail and Guardian Trust plc (DMGT), on the sale of its remaining 50% interest in its Radio business in Australia to Illyria Pty, a private investment company of Lachlan Murdoch. The Radio operations comprise two national music networks in Australia
21-Aug-12
$1.1 billion
Target:
Broadcast Rights for the National Rugby League
Acquiror:
Nine Network / Fox Sports
Advised the Australian Rugby League Commission on the sale of the Australian television broadcasting rights for the National Rugby League to Nine, a leading Free to Air broadcaster and Fox Sports, Australia’s largest pay TV broadcaster (partially owned by News Limited)
12-Jul-12
$5.0 billion
Target:
Aegis Group plc
Acquiror:
Dentsu Inc.
Advised Aegis Group plc, a leading global media and digital communications agency, on its sale to Dentsu Inc., the leading advertising group in Asia
21-Nov-11
$689 million
Target:
iNova Pharmaceuticals
Acquiror:
Valeant Pharmaceuticals
Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals
27-Jul-11
$850 million
Target:
The Synovate Group
Acquiror:
Ipsos S.A.
Advised Aegis Group plc on the sale of The Synovate Group, a leading global provider of custom market research, to Ipsos S.A.
15-Dec-10
$12.9 billion
Target:
Alcon, Inc.
Acquiror:
Novartis AG
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
26-Nov-10
$118 million
Target:
Healthcare Australia
Acquiror:
Healthcare Locums
Advised CHAMP Private Equity on the sale of Healthcare Australia, a leading provider of nursing agency staff to public and private health institutions in Australia, to Healthcare Locums, a healthcare recruitment agency based in the UK
21-Sep-10
$234 million
Target:
Taro Pharmaceutical Industries
Acquiror:
Sun Pharmaceutical Industries Ltd.
Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company
29-Jul-10
$328 million
Target:
Mitchell Communication Group Limited
Acquiror:
Aegis Group plc
Advised Aegis Group plc on its acquisition of Mitchell Communication Group Limited, Australia’s leading independent media buyer
01-Jul-10
$NA
Target:
Media Monitors
Acquiror:
Quadrant Private Equity
Advised Media Monitors, the leading media intelligence company in Asia-Pacific, on its sale to Quadrant Private Equity
04-Dec-09
$NA
Target:
Verivox Holding Limited
Acquiror:
Oakley Capital Private Equity LP
Advised the shareholders of Verivox Holdings Limited, comprising Independent News & Media plc and the founders and joint CEOs of Verivox, on the sale of 51% in Verivox, Germany’s leading price comparison website for energy and telecommunications services, to Oakley Capital Private Equity
09-Nov-09
$327 million
Target:
Enzon Pharmaceuticals, Inc.
Acquiror:
Sigma-Tau Pharmaceuticals
Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company
12-Mar-09
$46.9 billion
Target:
Genentech, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company